US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
Executive Summary
Dr Reddy’s can re-launch its generic version of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film in the US following a crucial court ruling that has gone its way. Indivior faces significant turbulence ahead if a generic entry materializes soon.
You may also be interested in...
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market
US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key
Massive reorganization efforts are underway at Dr Reddy’s as it recalibrates costs; an antibiotics site is expected to be sold soon as part of these efforts and more may be in store. Management commentary was, however, upbeat around the growth outlook for the US business, with visibility of 15-20 launches in FY 2019.